The world's worst outbreak of Ebola has killed nearly 1,000 people in
There is no proven cure or vaccine to prevent infection with Ebola and the scale of the current outbreak has prompted the
GSK's experimental vaccine has already produced promising results in animal studies involving primates and it is now due to enter initial Phase I testing in humans, pending approval from the
A company spokeswoman said yesterday that the trial should get underway "later this year", while GSK's partner the
Even if is fast-tracked, however, and emergency procedures are put in place, the new vaccine could not be ready for widespread deployment before 2015 — even assuming it works as well as hoped.
"It is right at the beginning of the development journey and still has a very long way to go," the GSK official said, declining to be drawn on a possible timeline for launch.
The investigational vaccine is based on a chimpanzee adenovirus into which two Ebola genes have been inserted, which means it contains no infectious Ebola virus material.
Adenoviruses are best known for causing the common cold.
Once the vaccine enters a cell and delivers its genetic payload, the two gene inserts produce a protein that generates an immune response in the body — but the adenovirus carrying the genes does not
GSK acquired the vaccine after buying Swiss-based biotech company Okairos for
Most Popular Stories
- Bently Creates Alabama Small Business Commission
- Is Alibaba's IPO Price a Fairytale?
- Kardashian: Kanye Never Told Fan in Wheelchair to Stand Up
- Los Angeles Angels Clinch Playoff Spot
- U.S. Producer Prices Held Steady in August
- When to Say No to Investors, Yes to Mentors
- U.S. Tobacco Growers Lose Last of Price Supports
- Scottish Leaders Scramble for Votes on Independence
- Sanctions Push Russian Ruble to Historic Low
- ISIS Grew Strong as al-Qaida Weakened